Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone

P. P. Feuillan, C. M. Foster, O. H. Pescovitz, K. D. Hench, T. Shawker, A. Dwyer, J. D. Malley, K. Barnes, Donald (Lynn) Loriaux, G. B. Cutler

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

The McCune-Albright syndrome is characterized by cafe au lait spots, fibrous dysplasia of bones, and sexual precocity. Girls with precocious puberty due to this syndrome have episodic increases in serum estrogen levels together with the formation of large ovarian cysts. The serum gonadotropin levels are typically suppressed, and the precocious puberty has not responded to treatment with long-acting analogues of luteinizing hormone-releasing hormone (LHRH). Encouraged by our initial success in a pilot study of one patient, we have now treated five girls with the McCune-Albright syndrome with the aromatase inhibitor testolactone, which blocks the synthesis of estrogens. Testolactone decreased the levels of circulating estradiol (P

Original languageEnglish (US)
Pages (from-to)1115-1119
Number of pages5
JournalNew England Journal of Medicine
Volume315
Issue number18
StatePublished - 1986
Externally publishedYes

Fingerprint

Testolactone
Polyostotic Fibrous Dysplasia
Precocious Puberty
Aromatase Inhibitors
Estrogens
Fibrous Dysplasia of Bone
Cafe-au-Lait Spots
Ovarian Cysts
Serum
Gonadotropins
Gonadotropin-Releasing Hormone
Estradiol
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Feuillan, P. P., Foster, C. M., Pescovitz, O. H., Hench, K. D., Shawker, T., Dwyer, A., ... Cutler, G. B. (1986). Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. New England Journal of Medicine, 315(18), 1115-1119.

Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. / Feuillan, P. P.; Foster, C. M.; Pescovitz, O. H.; Hench, K. D.; Shawker, T.; Dwyer, A.; Malley, J. D.; Barnes, K.; Loriaux, Donald (Lynn); Cutler, G. B.

In: New England Journal of Medicine, Vol. 315, No. 18, 1986, p. 1115-1119.

Research output: Contribution to journalArticle

Feuillan, PP, Foster, CM, Pescovitz, OH, Hench, KD, Shawker, T, Dwyer, A, Malley, JD, Barnes, K, Loriaux, DL & Cutler, GB 1986, 'Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone', New England Journal of Medicine, vol. 315, no. 18, pp. 1115-1119.
Feuillan PP, Foster CM, Pescovitz OH, Hench KD, Shawker T, Dwyer A et al. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. New England Journal of Medicine. 1986;315(18):1115-1119.
Feuillan, P. P. ; Foster, C. M. ; Pescovitz, O. H. ; Hench, K. D. ; Shawker, T. ; Dwyer, A. ; Malley, J. D. ; Barnes, K. ; Loriaux, Donald (Lynn) ; Cutler, G. B. / Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. In: New England Journal of Medicine. 1986 ; Vol. 315, No. 18. pp. 1115-1119.
@article{64aef538bab14fc7827eb13e7ecbde18,
title = "Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone",
abstract = "The McCune-Albright syndrome is characterized by cafe au lait spots, fibrous dysplasia of bones, and sexual precocity. Girls with precocious puberty due to this syndrome have episodic increases in serum estrogen levels together with the formation of large ovarian cysts. The serum gonadotropin levels are typically suppressed, and the precocious puberty has not responded to treatment with long-acting analogues of luteinizing hormone-releasing hormone (LHRH). Encouraged by our initial success in a pilot study of one patient, we have now treated five girls with the McCune-Albright syndrome with the aromatase inhibitor testolactone, which blocks the synthesis of estrogens. Testolactone decreased the levels of circulating estradiol (P",
author = "Feuillan, {P. P.} and Foster, {C. M.} and Pescovitz, {O. H.} and Hench, {K. D.} and T. Shawker and A. Dwyer and Malley, {J. D.} and K. Barnes and Loriaux, {Donald (Lynn)} and Cutler, {G. B.}",
year = "1986",
language = "English (US)",
volume = "315",
pages = "1115--1119",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "18",

}

TY - JOUR

T1 - Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone

AU - Feuillan, P. P.

AU - Foster, C. M.

AU - Pescovitz, O. H.

AU - Hench, K. D.

AU - Shawker, T.

AU - Dwyer, A.

AU - Malley, J. D.

AU - Barnes, K.

AU - Loriaux, Donald (Lynn)

AU - Cutler, G. B.

PY - 1986

Y1 - 1986

N2 - The McCune-Albright syndrome is characterized by cafe au lait spots, fibrous dysplasia of bones, and sexual precocity. Girls with precocious puberty due to this syndrome have episodic increases in serum estrogen levels together with the formation of large ovarian cysts. The serum gonadotropin levels are typically suppressed, and the precocious puberty has not responded to treatment with long-acting analogues of luteinizing hormone-releasing hormone (LHRH). Encouraged by our initial success in a pilot study of one patient, we have now treated five girls with the McCune-Albright syndrome with the aromatase inhibitor testolactone, which blocks the synthesis of estrogens. Testolactone decreased the levels of circulating estradiol (P

AB - The McCune-Albright syndrome is characterized by cafe au lait spots, fibrous dysplasia of bones, and sexual precocity. Girls with precocious puberty due to this syndrome have episodic increases in serum estrogen levels together with the formation of large ovarian cysts. The serum gonadotropin levels are typically suppressed, and the precocious puberty has not responded to treatment with long-acting analogues of luteinizing hormone-releasing hormone (LHRH). Encouraged by our initial success in a pilot study of one patient, we have now treated five girls with the McCune-Albright syndrome with the aromatase inhibitor testolactone, which blocks the synthesis of estrogens. Testolactone decreased the levels of circulating estradiol (P

UR - http://www.scopus.com/inward/record.url?scp=0022978603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022978603&partnerID=8YFLogxK

M3 - Article

C2 - 3093862

AN - SCOPUS:0022978603

VL - 315

SP - 1115

EP - 1119

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 18

ER -